These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 16751797

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder.
    Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y.
    J Pharmacol Sci; 2010; 112(2):128-34. PubMed ID: 20134115
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia.
    Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T.
    J Pharmacol Sci; 2015 Jun; 128(2):65-70. PubMed ID: 26084660
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo.
    Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, Eglen RM.
    Br J Pharmacol; 1997 Apr; 120(8):1409-18. PubMed ID: 9113359
    [Abstract] [Full Text] [Related]

  • 13. Antimuscarinic mechanisms and the overactive detrusor: an update.
    Andersson KE.
    Eur Urol; 2011 Mar; 59(3):377-86. PubMed ID: 21168951
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Developments in the medical treatment of overactive bladder].
    Alcántara Montero A.
    Semergen; 2016 Mar; 42(8):557-565. PubMed ID: 26671329
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment.
    Hartigan SM, Dmochowski RR.
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):103-110. PubMed ID: 31918590
    [Abstract] [Full Text] [Related]

  • 19. Which muscarinic receptor is important in the bladder?
    Yamanishi T, Chapple CR, Chess-Williams R.
    World J Urol; 2001 Nov; 19(5):299-306. PubMed ID: 11760777
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
    Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M.
    J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.